Ceapro Inc.
4046 RTF: 8308 - 114 Street
Edmonton
Alberta
T6G 2E1
Canada
Tel: 780-421-4555
Fax: 780-421-1320
Website: http://www.ceapro.com/
127 articles about Ceapro Inc.
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
3/12/2024
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
2/26/2024
Aeterna Zentaris Inc. and Ceapro Inc., two innovative biopharmaceutical development companies, are pleased to announce that leading independent proxy advisor Institutional Shareholder Services Inc. recommended that both companies’ securityholders vote FOR the all-stock merger of equals transaction pursuant to the terms announced on December 14, 2023.
-
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
2/23/2024
Ceapro Inc., provided an update on its progress across its current business.
-
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
2/15/2024
Aeterna Zentaris Inc. announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead of its special meeting of shareholders to approve its merger of equals transaction with Ceapro Inc.
-
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
12/14/2023
Aeterna Zentaris Inc. and Ceapro Inc., two innovative biopharmaceutical development companies, announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction.
-
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
12/13/2023
Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) today announced the commencement of patient dosing in its Phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.
-
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
11/29/2023
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.
-
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
11/27/2023
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.
-
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
11/7/2023
Ceapro Inc. announced the signing of a technical collaboration with Austria-based NATEX Prozesstechnologie GmbH to accelerate the scale-up of its proprietary PGX Technology towards commercial level.
-
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
8/29/2023
Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2023.
-
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
8/25/2023
Ceapro Inc. announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.
-
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
7/18/2023
Ceapro Inc. announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives.
-
Ceapro to Participate in the Virtual Investor Summer Spotlight SeriesLive moderated video webcast on Wednesday, July 12th at 1:00 PM ET
7/5/2023
Ceapro Inc. announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.
-
Ceapro Announces Results of 2023 Shareholders’ Meeting
6/7/2023
Ceapro Inc. announced that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 6, 2023 as per the following results.
-
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
5/25/2023
Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.
-
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
5/23/2023
Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).
-
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
5/3/2023
Ceapro Inc. announced positive results from a research collaboration with the Angiogenesis Foundation conducted with colleagues at the University of Arizona.
-
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
4/27/2023
Ceapro Inc. today announced the appointment of Michel (Mitch) Regnier as Senior Vice President, Technical Operations, effective May 1, 2023.
-
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
4/12/2023
Ceapro Inc.(TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.
-
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
3/23/2023
Ceapro Inc. announced that the abstract titled, “Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis,” has been accepted for a presentation at the American Thoracic Society International Conference to be held at the Walter E. Washington Convention Center in Washington, DC between May 19-24, 2023.